The University of Texas M.D. Anderson Cancer Center

What The University of Texas M.D. Anderson Cancer Center does

The University of Texas M.D. Anderson Cancer Center is a public academic medical center and one of the original three NCI-designated Comprehensive Cancer Centers in the United States, founded in 1941 and headquartered in the Texas Medical Center in Houston. It operates as part of The University of Texas System and serves cancer patients across all disease types and stages, plus referring physicians, international patients, and underserved community populations through dedicated programs. Its core offering is an integrated platform spanning direct patient care (surgery, chemotherapy, radiation, immunotherapy, targeted therapy), the nation's largest cancer clinical trials program (1,579 trials, 10,000+ enrolled patients in FY25), translational and basic science research across 30+ core facilities, and a Cancer Prevention Center with community outreach through the Be Well Communities coalition.

The underlying technology stack includes the PreCiSe CRISPR screening platform for engineering enhanced NK cell therapies, digital twin technology and surgical process modeling for planning cancer surgery, cone-beam CT combined with robotic-assisted bronchoscopy achieving over 90% diagnostic yield on lung nodule biopsies, and an Institute for Data Science in Oncology (IDSO) formalizing decision analytics. The James P. Allison Institute anchors 160+ immunotherapy and cellular therapy clinical trials, leveraging the work of 2018 Nobel laureate James P. Allison in immune checkpoint blockade. Distribution is primarily through direct care at the Houston campus, with extensions via the MD Anderson Cancer Network of partner institutions, the myMDAnderson/MyChart patient portal, a referring-physician portal, and a dedicated International Center.

Revenue is generated through a diversified mix rather than a single pricing model: patient care services via insurance reimbursement, self-pay, and government programs; sponsored clinical trial agreements, grants, and trial-related services; strategic research collaborations with pharmaceutical and biotechnology companies producing upfront, milestone, and royalty payments; and tuition and program fees for graduate medical, nursing, postdoctoral, and continuing education. Awards and recognition include the 36-year consecutive #1 U.S. News & World Report ranking in cancer care, NCI Comprehensive Cancer Center status with SPORE grants, and full AAHRPP accreditation of the human research protection program.

Name

The University of Texas M.D. Anderson Cancer Center

Legal name

The University of Texas MD Anderson Cancer Center

Website

https://mdanderson.org

Company type

Public

Founded year

1941

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The University of Texas M.D. Anderson Cancer Center is a public, NCI-designated Comprehensive Cancer Center in Houston, Texas, that delivers integrated cancer treatment, the nation's largest clinical trials program (1,579 active trials), translational and basic research, and prevention services to patients, referring physicians, and international patients worldwide.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Offices of Physicians (except Mental Health Specialists) (621111)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Cancer treatment services
• Oncology clinical trials
• Cancer prevention programs
• Immunotherapy research
• Translational cancer research

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Patient Care Services: Clinical care services including cancer treatment, surgery, immunotherapy, radiation therapy, and other medical services. Revenue generated through insurance reimbursement, self-pay, and government programs.
2. Clinical Trials Research: MD Anderson conducts over 1,579 clinical trials with more than 10,000 patients enrolled. Research generates revenue through sponsored research agreements, grants, and trial-related services.
3. Strategic Research Collaborations: Collaborative research agreements with pharmaceutical and biotechnology companies including upfront payments, milestone payments, and royalties on successful development.
4. Education and Training Programs: Graduate medical education, nursing education, postdoctoral training, and continuing professional education programs generating tuition and program fees.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

MD Anderson is a comprehensive cancer center delivering integrated cancer treatment (surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy), the nation's largest oncology clinical trials program, cancer prevention and screening services, basic science and translational research, and graduate medical education. The institution operates as a public academic medical center under The University of Texas System, treating patients across all cancer types and stages while translating laboratory discoveries into clinical applications.

Product overview

The University of Texas MD Anderson Cancer Center is a comprehensive cancer center offering a unified portfolio of cancer care services centered around its flagship hospital in Houston. The institution operates as an integrated platform combining direct patient treatment services (surgery, chemotherapy, immunotherapy, radiation therapy) with a vast clinical trials program (1,579 trials, 10,000+ patients). Core research divisions span Basic Science, Translational Research, and Clinical Research, supported by the James P. Allison Institute for immunotherapy innovation. Prevention services are delivered through the Cancer Prevention Center, while community health initiatives like Be Well Communities and THEAL extend reach into underserved populations. Digital patient engagement tools include MyChart and myMDAnderson for physicians, with the Cancer Network enabling geographic expansion through partner institutions.

Differentiator

Problem solved

Functional benefit

Brands

• James P. Allison Institute: A visionary research and innovation hub dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health.
• Be Well Communities
• Lyda Hill Cancer Prevention Center

Products and services

• Cancer Treatment Services Comprehensive cancer treatment including surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy for patients across all cancer types and stages. Care is delivered through multidisciplinary teams at the Houston campus and through the MD Anderson Cancer Network.
• Clinical Trials Program The nation's largest cancer clinical trials program, operating 1,579 active clinical trials with more than 10,000 patients enrolled. Provides patients with access to investigational therapies including immunotherapy drugs, CAR T cell therapies, and other novel oncology treatments years before they become standard of care.
• Lyda Hill Cancer Prevention Center Provides cancer risk assessment, screening, and diagnostic services including genetic testing and counseling for patients seeking to understand and manage their cancer risk.
• MD Anderson Cancer Network A network of partner institutions across the United States that allows MD Anderson to extend its expertise, enable enrollment of diverse patient populations in clinical trials, and deliver specialized cancer care beyond the Houston campus.
• Be Well Communities A place-based community cancer prevention strategy deploying science-based cancer prevention strategies to underserved communities, including programs in Baytown, Pasadena, and Acres Homes. Operates through coalition partners such as Harris Health System, Memorial Hermann Community Benefit Corporation, and UTHealth School of Public Health.
• Translational Research Services Translational research services that facilitate the movement of new ideas and treatments from laboratory to clinic, enabling collaboration between clinicians and scientists through strategic research agreements with pharmaceutical and biotechnology companies.
• Basic Science Research Discovery science that uncovers foundational knowledge in cellular and molecular biology, immunology, genetics, genomics, biochemistry, systems biology, and physiology, supported by over 30 core facilities providing cost-effective access to state-of-the-art instrumentation and services.
• James P. Allison Institute A research and innovation hub dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines, driving 160+ immunotherapy and cellular therapy clinical trials.

Quantifiable outcome

• 100% overall response rate with 57% complete remission in BALLI-01 trial target population
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Nine partnerships are on record, tiered core.

• C-Biomex Ltd.coreStrategic or Co-development Partner · 7 February 2024Collaborative research agreement to co-develop CBT-001, a radioligand therapy targeting CA9 cancer biomarker. MD Anderson provides translational radiopharmaceutical research expertise; C-Biomex provides its CUSTM peptide discovery platform. Plans preclinical studies to support FDA IND application.
• TheolyticscoreStrategic or Co-development PartnerMD Anderson researchers leading the Phase 1 OCTOPOD-IP trial of THEO-260 in platinum-resistant ovarian cancer. Theolytics is simultaneously conducting a Phase 1/2a OCTOPOD-IV trial exploring intravenous delivery across the UK, Spain, and Canada.
• Sibylla BiotechcoreStrategic or Co-development PartnerStrategic collaboration to discover and develop small-molecule protein degraders for cancer treatment.
• CureVaccoreStrategic or Co-development PartnerStrategic collaboration to develop novel cancer vaccines using CureVac's mRNA technology.
• Harris Health SystemcoreStrategic or Co-development PartnerCollaboration through Be Well Communities initiative and Texas Health Equity Alliance for Breast Cancer (THEAL) to reduce breast cancer disparities in Harris County.
• Memorial Hermann Community Benefit CorporationcoreStrategic or Co-development PartnerCoalition partner in Be Well Communities, a place-based strategy for cancer prevention and control targeting underserved communities.
• UTHealth School of Public HealthcoreStrategic or Co-development PartnerPartner in Be Well Communities coalition bringing public health expertise to community-based cancer prevention initiatives.
• Pan American Health Organization (PAHO)coreStrategic or Co-development PartnerCollaboration to support cancer prevention and control in the Americas, extending MD Anderson's global oncology efforts.
• Zambia Ministry of HealthcoreStrategic or Co-development PartnerGlobal oncology partnership expanding MD Anderson's international cancer care and research efforts.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dana-Farber Cancer Institute: Harvard-affiliated comprehensive cancer center with similar tripartite mission of research, treatment, and education; competes head-to-head for Northeast patients, NIH funding, and biopharma partnerships in hematology/oncology.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: Johns Hopkins-affiliated comprehensive cancer center with comparable depth in translational research, clinical trials, and specialty oncology services; competes for patients, federal grants, and industry partnerships.
• Fred Hutchinson Cancer Center: Seattle-based NCI-designated comprehensive cancer center known for bone marrow transplantation and immunotherapy research; comparable in research intensity and competes for biopharma-sponsored cell therapy trials and faculty.
• Memorial Sloan Kettering Cancer Center: The other leading NCI-designated comprehensive cancer center in the US, with a comparable mix of inpatient specialty oncology, outpatient treatment, and a large clinical trials program directly competing for patients, PIs, and industry-sponsored trials.
• City of Hope Comprehensive Cancer Center: California-based NCI-designated cancer center with strong translational research and CAR T cell therapy programs; comparable in clinical trial volume, immunotherapy focus, and academic affiliation.
• Stanford Cancer Institute: Stanford-affiliated NCI-designated comprehensive cancer center with strong translational research and clinical trial portfolio; comparable in academic affiliation, scientific talent, and biopharma partnership focus.
• UCSF Helen Diller Family Comprehensive Cancer Center: UCSF-affiliated NCI-designated comprehensive cancer center offering comparable specialty oncology care, translational research, and clinical trials in a major US academic medical hub.
• Roswell Park Comprehensive Cancer Center: One of the original NCI-designated comprehensive cancer centers, with similar mix of inpatient oncology, outpatient treatment, and research programs; comparable in mission and patient population.

Broad incumbents

• Mayo Clinic Comprehensive Cancer Center: Operates one of the largest integrated cancer programs within a broader multi-specialty academic medical system; comparable on clinical trial scale and translational research but anchored in a multi-state general hospital platform.
• Cleveland Clinic Taussig Cancer Center: Embedded within the broader Cleveland Clinic health system, Taussig offers oncology services, clinical trials, and translational research comparable in scope, though it sits inside a multi-specialty integrated delivery network.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/mdandersonnews
• YouTubeyoutube.com/user/mdanderson
• Facebookfacebook.com/MDAnderson
• LinkedInlinkedin.com/company/md-anderson-cancer-center

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The University of Texas M.D. Anderson Cancer Center